Ferroptosis, a new form of cell death, and its relationships with tumourous diseases

Journal of Cellular and Molecular Medicine

Volumn 21, Issue 4, 2017, Pages 648-657

  Yu, Haitao ^a   Guo, Pengyi ^a   Xie, Xiaozai ^a   Wang, Yi ^a   Chen, Gang ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

erastin; ferroptosis; iron dependent cell death; tumourous diseases

Indexed keywords

ARTEMISININ; CHAPERONIN 60; CHEMICAL COMPOUND; ERASTIN; HEAT SHOCK PROTEIN 100; HEAT SHOCK PROTEIN 40; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; MEVALONIC ACID; PHOSPHOLIPID HYDROPEROXIDE GLUTATHIONE PEROXIDASE; REACTIVE OXYGEN METABOLITE; SORAFENIB; SULFUR; UNCLASSIFIED DRUG; VOLTAGE DEPENDENT ANION CHANNEL 2; VOLTAGE DEPENDENT ANION CHANNEL 3; IRON;

APOPTOSIS; CELL DEATH; CELL PROLIFERATION; DIFFUSE LARGE B CELL LYMPHOMA; ENZYME INHIBITION; FERROPTOSIS; HUMAN; KIDNEY CARCINOMA; LIPID PEROXIDATION; LIVER CELL CARCINOMA; MALIGNANT NEOPLASM; NECROPTOSIS; NONHUMAN; OVARY CARCINOMA; PANCREAS CARCINOMA; PRIORITY JOURNAL; PSEUDOLYMPHOMA; REVIEW; TUMOR CELL; ANIMAL; BIOLOGICAL MODEL; METABOLISM; NECROSIS; NEOPLASM; PATHOLOGY;

ANIMALS; APOPTOSIS; HUMANS; IRON; METABOLIC NETWORKS AND PATHWAYS; MODELS, BIOLOGICAL; NECROSIS; NEOPLASMS;

EID: 85000658863     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.13008     Document Type: Review

References (92)

1. Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012; 149: 1060–72.
2. Yang WS, SriRamaratnam R, Welsch ME, et al. Regulation of ferroptotic cancer cell death by GPX4. Cell. 2014; 156: 317–31.
3. Lachaier E, Louandre C, Godin C, et al. Sorafenib induces ferroptosis in human cancer cell lines originating from different solid tumors. Anticancer Res. 2014; 34: 6417–22.
4. Ooko E, Saeed ME, Kadioglu O, et al. Artemisinin derivatives induce iron-dependent cell death (ferroptosis) in tumor cells. Phytomedicine. 2015; 22: 1045–54.
5. Yang WS, Stockwell BR. Ferroptosis: death by lipid peroxidation. Trends Cell Biol. 2015; 26: 165–76.
6. Eling N, Reuter L, Hazin J, et al. Identification of artesunate as a specific activator of ferroptosis in pancreatic cancer cells. Oncoscience J. 2015; 2: 517–32.
7. Louandre C, Marcq I, Bouhlal H, et al. The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells. Cancer Lett. 2015; 356: 971–7.
8. Frey PA, Reed GH. The ubiquity of iron. ACS Chem Biol. 2012; 7: 1477–81.
9. Bogdan AR, Miyazawa M, Hashimoto K, et al. Regulators of iron homeostasis: new players in metabolism, cell death, and disease. Trends Biochem Sci. 2016; 41: 274–86.
10. Manz DH, Blanchette NL, Paul BT, et al. Iron and cancer: recent insights. Ann N Y Acad Sci. 2016; 1368: 149–61.
11. Pratt DA, Tallman KA, Porter NA. Free radical oxidation of polyunsaturated lipids: new mechanistic insights and the development of peroxyl radical clocks. Acc Chem Res. 2011; 44: 458–67.
12. Ray PD, Huang B-W, Tsuji Y. Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. Cell Signal. 2012; 24: 981–90.
13. Dolma S, Lessnick SL, Hahn WC, et al. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell. 2003; 3: 285–96.
14. Yang WS, Stockwell BR. Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. Chem Biol. 2008; 15: 234–45.
15. Louandre C, Ezzoukhry Z, Godin C, et al. Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib. Int J Cancer. 2013; 133: 1732–42.
16. Abrams RP, Carroll WL, Woerpel KA. Five-membered ring peroxide selectively initiates ferroptosis in cancer cells. ACS Chem Biol. 2016; 11: 1305–12.
17. Cao JY, Dixon SJ. Mechanisms of ferroptosis. Cell mol Life sci. 2016; 73: 2195–209.
18. Xie Y, Hou W, Song X, et al. Ferroptosis: process and function. Cell Death Differ. 2016; 23: 369–79.
19. Galluzzi L, Vitale I, Abrams JM, et al. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ. 2012; 19: 107–20.
20. Kroemer G, Galluzzi L, Vandenabeele P, et al. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ. 2009; 16: 3–11.
21. da Fonseca RR, Kosiol C, Vinar T, et al. Positive selection on apoptosis related genes. FEBS Lett. 2010; 584: 469–76.
22. Yan N, Shi Y. Mechanisms of apoptosis through structural biology. Annu Rev Cell Dev Biol. 2005; 21: 35–56.
23. Hitomi J, Christofferson DE, Ng A, et al. Identification of a molecular signaling network that regulates a cellular necrotic cell death pathway. Cell. 2008; 135: 1311–23.
24. Vercammen D, Vandenabeele P, Beyaert R, et al. Tumour necrosis factor-induced necrosis versus anti-Fas-induced apoptosis in L929 cells. Cytokine. 1997; 9: 801–8.
25. Kawahara A, Ohsawa Y, Matsumura H, et al. Caspase-independent cell killing by Fas-associated protein with death domain. J Cell Biol. 1998; 143: 1353–60.
26. Degterev A, Huang Z, Boyce M, et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol. 2005; 1: 112–9.
27. Klionsky DJ, Cregg JM, Dunn WA Jr, et al. A unified nomenclature for yeast autophagy-related genes. Dev Cell. 2003; 5: 539–45.
28. Sarkar S, Floto RA, Berger Z, et al. Lithium induces autophagy by inhibiting inositol monophosphatase. J Cell Biol. 2005; 170: 1101–11.
29. Wang C, Hu Q, Shen HM. Pharmacological inhibitors of autophagy as novel cancer therapeutic agents. Pharmacol Res. 2016; 105: 164–75.
30. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972; 26: 239–57.
31. Schweichel JU, Merker HJ. The morphology of various types of cell death in prenatal tissues. Teratology. 1973; 7: 253–66.
32. Clarke PG. Developmental cell death: morphological diversity and multiple mechanisms. Anat Embryol. 1990; 181: 195–213.
33. Shimada K, Hayano M, Pagano NC, et al. Cell-line selectivity improves the predictive power of pharmacogenomic analyses and helps identify NADPH as biomarker for ferroptosis sensitivity. Cell Chem Biol. 2016; 23: 225–35.
34. Dong T, Liao D, Liu X, et al. Using small molecules to dissect non-apoptotic programmed cell death: necroptosis, ferroptosis, and pyroptosis. Chembiochem. 2015; 16: 2557–61.
35. Torii S, Shintoku R, Kubota C, et al. An essential role for functional lysosomes in ferroptosis of cancer cells. Biochem J. 2016; 473: 769–77.
36. Sato H, Tamba M, Ishii T, et al. Cloning and expression of a plasma membrane cystine/glutamate exchange transporter composed of two distinct proteins. J Biol Chem. 1999; 274: 11455–8.
37. Bridges RJ, Natale NR, Patel SA. System xc(-) cystine/glutamate antiporter: an update on molecular pharmacology and roles within the CNS. Br J Pharmacol. 2012; 165: 20–34.
38. Lo M, Ling V, Wang YZ, et al. The xc- cystine/glutamate antiporter: a mediator of pancreatic cancer growth with a role in drug resistance. Br J Cancer. 2008; 99: 464–72.
39. Ishii T, Bannai S, Sugita Y. Mechanism of growth stimulation of L1210 cells by 2-mercaptoethanol in vitro. Role of the mixed disulfide of 2-mercaptoethanol and cysteine. J Biol Chem. 1981; 256: 12387–92.
40. Tan S, Schubert D, Maher P. Oxytosis: a novel form of programmed cell death. Curr Top Med Chem. 2001; 1: 497–506.
41. Dixon SJ, Stockwell BR. The role of iron and reactive oxygen species in cell death. Nat Chem Biol. 2014; 10: 9–17.
42. Murphy TH, Miyamoto M, Sastre A, et al. Glutamate toxicity in a neuronal cell line involves inhibition of cystine transport leading to oxidative stress. Neuron. 1989; 2: 1547–58.
43. Bannai S, Kitamura E. Transport interaction of L-cystine and L-glutamate in human diploid fibroblasts in culture. J Biol Chem. 1980; 255: 2372–6.
44. Wolpaw AJ, Shimada K, Skouta R, et al. Modulatory profiling identifies mechanisms of small molecule-induced cell death. Proc Natl Acad Sci USA. 2011; 108: E771–80.
45. Ursini F, Maiorino M, Valente M, et al. Purification from pig liver of a protein which protects liposomes and biomembranes from peroxidative degradation and exhibits glutathione peroxidase activity on phosphatidylcholine hydroperoxides. Biochim Biophys Acta. 1982; 710: 197–211.
46. Thomas JP, Geiger PG, Maiorino M, et al. Enzymatic reduction of phospholipid and cholesterol hydroperoxides in artificial bilayers and lipoproteins. Biochim Biophys Acta. 1990; 1045: 252–60.
47. Ursini F, Maiorino M, Brigelius-Flohe R, et al. Diversity of glutathione peroxidases. Methods Enzymol. 1995; 252: 38–53.
48. Brigelius-Flohe R, Maiorino M. Glutathione peroxidases. Biochim Biophys Acta. 1830; 2013: 3289–303.
49. Weiwer M, Bittker JA, Lewis TA, et al. Development of small-molecule probes that selectively kill cells induced to express mutant RAS. Bioorg Med Chem Lett. 2012; 22: 1822–6.
50. Yang WS, Shimada K, Delva D, et al. Identification of simple compounds with microtubule-binding activity that inhibit cancer cell growth with high potency. ACS Med Chem Lett. 2012; 3: 35–8.
51. Baker MA, Lane DJ, Ly JD, et al. VDAC1 is a transplasma membrane NADH-ferricyanide reductase. J Biol Chem. 2004; 279: 4811–9.
52. Graham BH, Craigen WJ. Genetic approaches to analyzing mitochondrial outer membrane permeability. Curr Top Dev Biol. 2004; 59: 87–118.
53. Yagoda N, von Rechenberg M, Zaganjor E, et al. RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. Nature. 2007; 447: 864–8.
54. Jiang L, Hickman JH, Wang SJ, et al. Dynamic roles of p53-mediated metabolic activities in ROS-induced stress responses. Cell Cycle (Georgetown, Tex). 2015; 14: 2881–5.
55. Jiang L, Kon N, Li T, et al. Ferroptosis as a p53-mediated activity during tumour suppression. Nature. 2015; 520: 57–62.
56. Kryukov GV, Castellano S, Novoselov SV, et al. Characterization of mammalian selenoproteomes. Science (New York, NY). 2003; 300: 1439–43.
57. Warner GJ, Berry MJ, Moustafa ME, et al. Inhibition of selenoprotein synthesis by selenocysteine tRNA[Ser]Sec lacking isopentenyladenosine. J Biol Chem. 2000; 275: 28110–9.
58. McBean GJ. The transsulfuration pathway: a source of cysteine for glutathione in astrocytes. Amino Acids. 2012; 42: 199–205.
59. Shoveller AK, Brunton JA, House JD, et al. Dietary cysteine reduces the methionine requirement by an equal proportion in both parenterally and enterally fed piglets. J Nutr. 2003; 133: 4215–24.
60. Ball RO, Courtney-Martin G, Pencharz PB. The in vivo sparing of methionine by cysteine in sulfur amino acid requirements in animal models and adult humans. J Nutr. 2006; 136: 1682s–93s.
61. Hayano M, Yang WS, Corn CK, et al. Loss of cysteinyl-tRNA synthetase (CARS) induces the transsulfuration pathway and inhibits ferroptosis induced by cystine deprivation. Cell Death Differ. 2016; 23: 270–8.
62. Carver JA, Rekas A, Thorn DC, et al. Small heat-shock proteins and clusterin: intra- and extracellular molecular chaperones with a common mechanism of action and function? IUBMB Life. 2003; 55: 661–8.
63. Jakob U, Gaestel M, Engel K, et al. Small heat shock proteins are molecular chaperones. J Biol Chem. 1993; 268: 1517–20.
64. Wu C. Heat shock transcription factors: structure and regulation. Annu Rev Cell Dev Biol. 1995; 11: 441–69.
65. Sun X, Ou Z, Xie M, et al. HSPB1 as a novel regulator of ferroptotic cancer cell death. Oncogene. 2015; 34: 5617–25.
66. Gao M, Monian P, Jiang X. Metabolism and iron signaling in ferroptotic cell death. Oncotarget. 2015; 6: 35145–6.
67. Gao M, Monian P, Quadri N, et al. Glutaminolysis and transferrin regulate ferroptosis. Mol Cell. 2015; 59: 298–308.
68. Sun X, Ou Z, Chen R, et al. Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells. Hepatology (Baltimore, MD). 2016; 63: 173–84.
69. Hasegawa M, Takahashi H, Rajabi H, et al. Functional interactions of the cystine/glutamate antiporter, CD44v and MUC1-C oncoprotein in triple-negative breast cancer cells. Oncotarget. 2016; 7: 11756–69.
70. Kwon MY, Park E, Lee SJ, et al. Heme oxygenase-1 accelerates erastin-induced ferroptotic cell death. Oncotarget. 2015; 6: 24393–403.
71. Linkermann A, Skouta R, Himmerkus N, et al. Synchronized renal tubular cell death involves ferroptosis. Proc Natl Acad Sci USA. 2014; 111: 16836–41.
72. Friedmann Angeli JP, Schneider M, Proneth B, et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat Cell Biol. 2014; 16: 1180–91.
73. Skouta R, Dixon SJ, Wang J, et al. Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models. J Am Chem Soc. 2014; 136: 4551–6.
74. Yamaguchi H, Hsu JL, Chen CT, et al. Caspase-independent cell death is involved in the negative effect of EGF receptor inhibitors on cisplatin in non-small cell lung cancer cells. Clin Cancer Res. 2013; 19: 845–54.
75. Chen L, Li X, Liu L, et al. Erastin sensitizes glioblastoma cells to temozolomide by restraining xCT and cystathionine-gamma-lyase function. Oncol Rep. 2015; 33: 1465–74.
76. Iglehart JK, York RM, Modest AP, et al. Cystine requirement of continuous human lymphoid cell lines of normal and leukemic origin. J Biol Chem. 1977; 252: 7184–91.
77. Gout PW, Buckley AR, Simms CR, et al. Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)- cystine transporter: a new action for an old drug. Leukemia. 2001; 15: 1633–40.
78. Gout PW, Simms CR, Robertson MC. In vitro studies on the lymphoma growth-inhibitory activity of sulfasalazine. Anticancer Drugs. 2003; 14: 21–9.
79. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69–90.
80. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet (London, England). 2012; 379: 1245–55.
81. Dixon SJ, Patel DN, Welsch M, et al. Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. Elife. 2014; 3: e02523.
82. Knudsen ES, Knudsen KE. Tailoring to RB: tumour suppressor status and therapeutic response. Nat Rev Cancer. 2008; 8: 714–24.
83. Mayhew CN, Carter SL, Fox SR, et al. RB loss abrogates cell cycle control and genome integrity to promote liver tumorigenesis. Gastroenterology. 2007; 133: 976–84.
84. Viatour P, Ehmer U, Saddic LA, et al. Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway. J Exp Med. 2011; 208: 1963–76.
85. Ezzoukhry Z, Louandre C, Trecherel E, et al. EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib. Int J Cancer. 2012; 131: 2961–9.
86. Godin C, Dupont S, Ezzoukhry Z, et al. Heterogeneous sensitivity of hepatocellular carcinoma to sorafenib revealed by the short-term culture of tumor fragments. Anticancer Res. 2013; 33: 1415–20.
87. Galmiche A, Chauffert B, Barbare JC. New biological perspectives for the improvement of the efficacy of sorafenib in hepatocellular carcinoma. Cancer Lett. 2014; 346: 159–62.
88. Coriat R, Nicco C, Chereau C, et al. Sorafenib-induced hepatocellular carcinoma cell death depends on reactive oxygen species production in vitro and in vivo. Mol Cancer Ther. 2012; 11: 2284–93.
89. Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov. 2006; 5: 835–44.
90. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997; 15: 2403–13.
91. Greenshields AL, Shepherd TG, Hoskin DW. Contribution of reactive oxygen species to ovarian cancer cell growth arrest and killing by the anti-malarial drug artesunate. Mol Carcinog. 2016; doi: 10.1002/mc.22474.
92. Schott C, Graab U, Cuvelier N, et al. Oncogenic RAS mutants confer resistance of RMS13 rhabdomyosarcoma cells to oxidative stress-induced ferroptotic cell death. Front Oncol. 2015; 5: 131.